196 related articles for article (PubMed ID: 32646514)
1. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
Boichard A; Wagner MJ; Kurzrock R
Genome Med; 2020 Jul; 12(1):61. PubMed ID: 32646514
[TBL] [Abstract][Full Text] [Related]
2. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
[TBL] [Abstract][Full Text] [Related]
3. The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
Painter CA; Jain E; Tomson BN; Dunphy M; Stoddard RE; Thomas BS; Damon AL; Shah S; Kim D; Gómez Tejeda Zañudo J; Hornick JL; Chen YL; Merriam P; Raut CP; Demetri GD; Van Tine BA; Lander ES; Golub TR; Wagle N
Nat Med; 2020 Feb; 26(2):181-187. PubMed ID: 32042194
[TBL] [Abstract][Full Text] [Related]
4. Comparative Genomics Reveals Shared Mutational Landscape in Canine Hemangiosarcoma and Human Angiosarcoma.
Megquier K; Turner-Maier J; Swofford R; Kim JH; Sarver AL; Wang C; Sakthikumar S; Johnson J; Koltookian M; Lewellen M; Scott MC; Schulte AJ; Borst L; Tonomura N; Alfoldi J; Painter C; Thomas R; Karlsson EK; Breen M; Modiano JF; Elvers I; Lindblad-Toh K
Mol Cancer Res; 2019 Dec; 17(12):2410-2421. PubMed ID: 31570656
[TBL] [Abstract][Full Text] [Related]
5. Current and Future Directions for Angiosarcoma Therapy.
Florou V; Wilky BA
Curr Treat Options Oncol; 2018 Mar; 19(3):14. PubMed ID: 29520447
[TBL] [Abstract][Full Text] [Related]
6. Current Management of Angiosarcoma: Recent Advances and Lessons From the Past.
Florou V; Wilky BA
Curr Treat Options Oncol; 2021 Jun; 22(7):61. PubMed ID: 34097172
[TBL] [Abstract][Full Text] [Related]
7. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
Front Immunol; 2021; 12():657575. PubMed ID: 33936087
[TBL] [Abstract][Full Text] [Related]
8. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
Chan JY; Lim JQ; Yeong J; Ravi V; Guan P; Boot A; Tay TKY; Selvarajan S; Md Nasir ND; Loh JH; Ong CK; Huang D; Tan J; Li Z; Ng CC; Tan TT; Masuzawa M; Sung KW; Farid M; Quek RHH; Tan NC; Teo MCC; Rozen SG; Tan P; Futreal A; Teh BT; Soo KC
J Clin Invest; 2020 Nov; 130(11):5833-5846. PubMed ID: 33016928
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
[TBL] [Abstract][Full Text] [Related]
10. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
[TBL] [Abstract][Full Text] [Related]
11. Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.
Boutros C; Rouleau E; Majer M; Nikolaev S; Robert C
Eur J Cancer; 2021 Jun; 150():130-132. PubMed ID: 33901791
[No Abstract] [Full Text] [Related]
12. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
Yan C; Richmond A
Mol Cancer; 2021 Nov; 20(1):146. PubMed ID: 34758832
[TBL] [Abstract][Full Text] [Related]
13. Active TGF-β signaling and decreased expression of PTEN separates angiosarcoma of bone from its soft tissue counterpart.
Verbeke SL; Bertoni F; Bacchini P; Oosting J; Sciot R; Krenács T; Bovée JV
Mod Pathol; 2013 Sep; 26(9):1211-21. PubMed ID: 23599148
[TBL] [Abstract][Full Text] [Related]
14. Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report.
Guan J; Luo Z; Xiao Z; Xie Y; Lin L
BMC Cancer; 2019 Dec; 19(1):1188. PubMed ID: 31805975
[TBL] [Abstract][Full Text] [Related]
15. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
[TBL] [Abstract][Full Text] [Related]
16. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Olbryt M; Rajczykowski M; Widłak W
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
[TBL] [Abstract][Full Text] [Related]
17. Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.
Prenen H; Smeets D; Mazzone M; Lambrechts D; Sagaert X; Sciot R; Debiec-Rychter M
Oncotarget; 2015 Nov; 6(34):36418-25. PubMed ID: 26474454
[TBL] [Abstract][Full Text] [Related]
18. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Pender A; Titmuss E; Pleasance ED; Fan KY; Pearson H; Brown SD; Grisdale CJ; Topham JT; Shen Y; Bonakdar M; Taylor GA; Williamson LM; Mungall KL; Chuah E; Mungall AJ; Moore RA; Lavoie JM; Yip S; Lim H; Renouf DJ; Sun S; Holt RA; Jones SJM; Marra MA; Laskin J
Clin Cancer Res; 2021 Jan; 27(1):202-212. PubMed ID: 33020056
[TBL] [Abstract][Full Text] [Related]
19. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
20. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
